The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Major breakthroughs in AL amyloidosis treatment from ASH 2017
Several major breakthroughs in the treatment of amyloid light-chain (AL) amyloidosis were presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. In this interview, Laurent Garderet, MD, PhD, of Saint Antoine Hospital, Paris, France, provides an overview of the exciting updates from the meeting, including new understanding of the disease, promising new treatment results with daratumumab and what these advances mean for amyloidosis treatment.
